CN107261079B - Application of longhurendan in preparation of medicine for preventing and/or treating diabetes - Google Patents
Application of longhurendan in preparation of medicine for preventing and/or treating diabetes Download PDFInfo
- Publication number
- CN107261079B CN107261079B CN201710301073.8A CN201710301073A CN107261079B CN 107261079 B CN107261079 B CN 107261079B CN 201710301073 A CN201710301073 A CN 201710301073A CN 107261079 B CN107261079 B CN 107261079B
- Authority
- CN
- China
- Prior art keywords
- longhurendan
- preventing
- treating diabetes
- diabetes
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an application of Longhu Rendan in preparing a medicament for preventing and/or treating diabetes, belonging to the technical field of preparation of medicaments for treating diabetes. The application of the Longhurendan in preparing the medicine for preventing and/or treating diabetes can realize the protection effect of the Longhurendan on islet cells and the improvement of the molecular mechanism of the Longhurendan on insulin resistance.
Description
Technical Field
The invention relates to the technical field of preparation of diabetes drugs, in particular to application of Longhu minium in preparation of a drug for preventing and/or treating diabetes.
Background
Diabetes mellitus is a chronic non-infectious disease which is the third most serious threat to human health after tumor and cardiovascular diseases. Diabetes mellitus is a chronic metabolic disease that results in hyperglycemia when the pancreas is unable to produce enough insulin or when the body is unable to use insulin effectively, with persistent hyperglycemia ultimately leading to multiple organ damage, and a particularly severe involvement of the blood vessels and nervous system.
The number of patients with diabetes is rapidly rising at present, and diabetes and its complications bring a heavy burden to human health and social development. According to the international diabetes union (IDF) statistics, 1.51 million diabetics worldwide in 2000 and up to 2.85 million are present, and at the present rate of growth, nearly 5 million people worldwide are expected to suffer from diabetes by 2030. It is noteworthy that diabetes is not just "an affluent disease" in developed countries. A research paper on journal of American medical society indicates that in 2013, the number of diabetic patients in China is as high as 1.14 hundred million, and 11 people in each hundred are diabetic patients. Diabetes is divided into type 1 and type 2, and type 1 diabetes is also called insulin-dependent diabetes, and the quality of life and the life span of a patient can be ensured only by clinically injecting insulin for treatment and matching with reasonable diet control and exercise. Type 2 diabetes, also known as non-insulin dependent diabetes, is a metabolic disease. Due to aging of population, prevalence of obesity and unhealthy life style, the incidence of type 2 diabetes in China is rising year by year, and currently, the incidence of type 2 diabetes is up to 1.1 hundred million people, and accounts for 93-95% of diabetes patients in China. The world-wide famous pharmaceutical and healthcare consultant, Decision Resources, indicates that the current type 2 diabetes drug market in china is about 150 billion RMB, and will grow at a 10% annual growth rate, reaching 220 billion RMB in 2017.
At present, the main drugs for treating diabetes are insulin secretion promoters (sulfonylureas, repaglinide), insulin sensitizers (biguanides, thiazolidinediones) and glucosidase inhibitors (acarbose), but they often have side effects of different degrees, such as hypoglycemia, weight gain, cardiovascular and rhabdomyolysis, etc.
Disclosure of Invention
The invention aims to provide application of longhurian Dan in preparation of a medicament for preventing and/or treating diabetes and provides application of a medicament which has small side effect and has a protective effect on islet cells.
The invention provides application of Longhu minium in preparing a medicament for preventing and/or treating diabetes.
Preferably, each 1000g of the Longhurendan comprises the following components in parts by mass: 32-48 g of menthol, 24-36 g of borneol, 20-30 g of clove, 20-30 g of fructus amomi, 12-18 g of star anise, 32-48 g of cinnamon, 12-18 g of pepper, 12-18 g of elecampane, 20-30 g of dried ginger, 160-240 g of catechu, 291.28-436.92 g of liquorice, 144-216 g of glutinous rice flour, 4-6 g of sodium benzoate, 11.6-17.4 g of red ferric oxide, 0.08-0.12 ml of simethicone, 0.16-0.24 g of graphite, 0.16-0.24 g of talcum powder and 3.16-4.74 g of dextrin.
Preferably, the formulation of the Longhurendan comprises tablets, powders, granules, pills and capsules.
Preferably, the effective dose of the Longhurendan is 100 mg/kg.
The invention provides application of Longhu minium in preparing a medicament for preventing and/or treating diabetes. In the present invention, the Longhurendan can improve oral glucose tolerance in normal mice. The Longhu minium is prepared into the medicine for preventing and/or treating diabetes, and is expected to improve the insulin resistance of the diabetic, reduce the risk of blood sugar and complications and greatly improve the life quality of the diabetic.
Drawings
FIG. 1 is a graph showing the effect of Longhurendan (LHRD) on blood glucose in normal mice according to example 1 of the present invention.
Detailed Description
The invention provides an application of Longhu rendan in preparing a medicament for preventing and/or treating diabetes.
In the invention, each 1000g of the Longhurendan comprises the following components in parts by mass: 32-48 g of menthol, 24-36 g of borneol, 20-30 g of clove, 20-30 g of fructus amomi, 12-18 g of star anise, 32-48 g of cinnamon, 12-18 g of pepper, 12-18 g of elecampane, 20-30 g of dried ginger, 160-240 g of catechu, 291.28-436.92 g of liquorice, 144-216 g of glutinous rice flour, 4-6 g of sodium benzoate, 11.6-17.4 g of red ferric oxide, 0.08-0.12 ml of simethicone, 0.16-0.24 g of graphite, 0.16-0.24 g of talcum powder and 3.16-4.74 g of dextrin. The source of the Longhurendan is not particularly limited in the invention, and the Longhurendan can be obtained by using a commercial product of the Longhurendan well known to those skilled in the art, such as the Longhurendan sold by Shanghai China pharmaceutical industry Co. The conventional effects of the Longhu Rendan in the prior art are resuscitation inducing and refreshing, dampness eliminating and turbid resolving, and stomach regulating and vomiting relieving effects, and the Longhu Rendan has the effects of regulating spleen and stomach, resolving turbid and strengthening transportation; in the invention, the Longhurendan can realize the preparation of the medicine for preventing and/or treating diabetes. It has been reported that ginger can enhance the sensitivity of body insulin [1-2 ]; cinnamon improves blood glucose and insulin resistance in diabetes by inhibiting oxidative stress in vivo [3-4 ]; catechu also has hypoglycemic effect [5 ]; licorice prevents diabetes and improves diabetic blood glucose by activating PPAR-gamma ligand activity [6 ]; in a hyperglycemic rat model, amomum villosum has hypoglycemic, hypolipidemic, blood creatinine, and liver enzyme activities [7 ].
In the invention, the dosage form of the Longhurendan comprises tablets, powder, granules, pills and capsules.
In the invention, the effective acting dosage of the Longhurendan is 100 mg/kg.
The preparation method is not particularly limited, and the preparation method of the commercial product of the Longhurendan which is well known by the technical personnel in the field can be adopted. The preparation method can refer to the limitation of the preparation method in the patent with the application number of 200910194559.1, and specifically comprises the following steps: (1) preparing a soft material: a. preparing the infant tea slurry: mixing and stirring the catechu and the purified water according to the mass ratio of 1: 1, controlling the steam pressure to be 0.25-0.5 Mpa and the temperature to be 60-95 ℃, heating to dissolve, and filtering to obtain a catechu solution; then stirring the sodium benzoate, the catechu solution and 5-18% of the glutinous rice flour in batches for 3-5 minutes, pulping for 10-30 minutes, and discharging; b. preparing mixed powder: mixing the glutinous rice flour, the fructus amomi powder, the star anise powder, the cinnamon powder, the pepper powder, the wood spice powder, the dried ginger powder, the clove powder and the liquorice powder in parts by mass, spraying the volatile raw materials which are melted and filtered in advance, mixing while spraying, and discharging after spraying is finished; c. mixing and stirring the mixed powder and the catechu pulp for 15-30 minutes, and discharging; (2) preparation of the pill: a. making the soft material into round and uniform wet hair pills; b. polishing the wet hair pills, adding a dextrin solution, uniformly stirring, blowing, rolling until the surface is bright, then scattering red ferric oxide, and then dripping simethicone into the mixture, wherein the coating time is 0.5-2.5 hours; c. drying and sterilizing, selecting pills with the diameter of 4.0-4.5 mm, adding graphite powder and talcum powder and polishing.
The application of the longhurendan provided by the invention in preparing a medicament for preventing and/or treating diabetes is further described in detail with reference to the following specific examples, and the technical scheme of the invention includes but is not limited to the following examples.
Example 1
Experimental animals: SPF grade ICR mice and spontaneous diabetic db/db mice, 8 weeks old, male, Guangdong province medical laboratory animal center.
Experimental drugs and reagents are shown in table 1:
TABLE 1 test drugs and reagents
The experimental equipment is shown in table 2:
TABLE 2 Experimental Equipment
Experimental protocol
(1) Effects of Longhurendan on glucose tolerance and insulin tolerance in Normal Kunming mice
Selecting male Kunming mice qualified for quarantine, weighing 18-22 g, after fasting (without water prohibition) for 12 hours, randomly dividing the mice into 3 groups (the difference between groups is not more than 1.1mmol/L) according to the blood sugar level, wherein the groups are a normal group, a metformin positive control group and a Longhu minium (100mg/kg), and each group is 8. The metformin group was administered at a dose of 0.2mg/kg, and the normal group was administered with an equal volume of vehicle control. Each test animal was administered by gavage in a volume of 10. mu.l/g.
Glucose Tolerance Test (OGTT): after administration of the drug for 4 hours, the mice in each test group were perfused with gastric glucose (2g/kg, 200mg/ml glucose solution, 10. mu.l/g) and the timing was started, blood was collected from the mouse tail vein at 0, 15, 30, 60, and 120min, respectively, and the blood glucose levels of the mice were measured with a glucometer (Qiangsheng Co.). The data were processed using software GraphPad Prism to make a line plot of the change in blood glucose and calculate the area under the curve to give the AUC.
FIG. 1 is a graph showing the effect of Longhurendan (LHRD) on blood glucose in normal mice. The results from fig. 1 show that: compared with a blank control group (control), the OGTT curve time period (0-120min) and the area under the curve (AUC) of the positive drug Metformin (Metformin) and the test drug Longhusandong (LHRD) are both obviously reduced (P is less than 0.01), and the blood glucose reducing effect of the LHRD is equivalent to that of Metformin. The Longhu Rendan has good blood sugar regulating effect. In fig. 1, fig. 1A is a glucose tolerance test OGTT; fig. 1B is the area AUC under the glucose tolerance curve. P <0.05vs. control mice.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (3)
1. Application of LONGHURENDAN in preparing medicine for preventing and/or treating diabetes is provided.
2. The use according to claim 1, characterized in that said Longhurendan is made up of the following ingredients per 1000 g: 32-48 g of menthol, 24-36 g of borneol, 20-30 g of clove, 20-30 g of fructus amomi, 12-18 g of star anise, 32-48 g of cinnamon, 12-18 g of pepper, 12-18 g of elecampane, 20-30 g of dried ginger, 160-240 g of catechu, 291.28-436.92 g of liquorice, 144-216 g of glutinous rice flour, 4-6 g of sodium benzoate, 11.6-17.4 g of red ferric oxide, 0.08-0.12 ml of simethicone, 0.16-0.24 g of graphite, 0.16-0.24 g of talcum powder and 3.16-4.74 g of dextrin.
3. The use of claim 1, wherein the effective amount of said Longhurendan is 100mg/k g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710301073.8A CN107261079B (en) | 2017-05-02 | 2017-05-02 | Application of longhurendan in preparation of medicine for preventing and/or treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710301073.8A CN107261079B (en) | 2017-05-02 | 2017-05-02 | Application of longhurendan in preparation of medicine for preventing and/or treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107261079A CN107261079A (en) | 2017-10-20 |
| CN107261079B true CN107261079B (en) | 2021-01-26 |
Family
ID=60074063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710301073.8A Active CN107261079B (en) | 2017-05-02 | 2017-05-02 | Application of longhurendan in preparation of medicine for preventing and/or treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107261079B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108421017A (en) * | 2018-05-09 | 2018-08-21 | 上海中华药业有限公司 | Application of the dragon and tiger jintan in preparing reducing blood lipid and artery plaque drug |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101637607A (en) * | 2009-08-25 | 2010-02-03 | 上海中华药业有限公司 | Dragon and tiger rentan plant medicine composition, preparation method and application thereof |
-
2017
- 2017-05-02 CN CN201710301073.8A patent/CN107261079B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101637607A (en) * | 2009-08-25 | 2010-02-03 | 上海中华药业有限公司 | Dragon and tiger rentan plant medicine composition, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107261079A (en) | 2017-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006098604A1 (en) | Pharmaceutical composition for preventing and treating diabetes or glucose control abnormality comprising ginsenosides | |
| KR102121153B1 (en) | Dietary herbal composition, dietary herbal medicine pill comprising the same and method for manufacturing thereof | |
| CN103608024B (en) | Control the pharmaceutical composition of blood glucose, blood fat and body weight | |
| KR20160007728A (en) | Method for manufacturing garlic skin extract and food composition for preventing and alleviating diabetes prepared using the same | |
| CN105380918B (en) | It is a kind of with blood sugar reducing health function acanthopanax trifoliatus polysaccharide tablet and preparation method thereof | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN108403818B (en) | Composition for assisting in reducing blood sugar and application thereof | |
| CN107261079B (en) | Application of longhurendan in preparation of medicine for preventing and/or treating diabetes | |
| CN105395706A (en) | Health care product for diabetes | |
| CN109223811B (en) | Ginsenoside composition with hypoglycemic activity | |
| CN101204571B (en) | Edible Chinese traditional medicine composite for diabetes mellitus and preparation method thereof | |
| CN109010514A (en) | Composition, health care product and the preparation method of altitude sickness prevention | |
| CN107693555A (en) | A kind of medicine and purposes for treating diabetes | |
| CN105168739B (en) | A kind of treat hypertension, hyperlipidemia, hyperglycemia and the compositions of resisting fatigue improving eyesight | |
| CN107875350B (en) | A Chinese medicinal composition for treating diabetes | |
| CN109260205B (en) | Application of tetrandrine in preparation of medicine for resisting diabetes and hypertension | |
| KR20130041494A (en) | The composition for treating diabetes | |
| CN107496510B (en) | Cyclocarya paliurus capsule and preparation method thereof | |
| KR20040003888A (en) | Composition of crude drug, method of preparing the same and pharmaceutical preparation including the same for curing diabetes mellitus | |
| CN101618063A (en) | Medicine for treating prostate gland diseases and preparation method thereof | |
| CN107233542B (en) | Application of longhurendan in preparing medicine for preventing and/or treating hepatic fibrosis | |
| CN104324278A (en) | Production method of antiobesity drug and antiobesity granules | |
| CN1327879C (en) | Medicine for treating diabetes and its preparing method | |
| CN110215470A (en) | A kind of preparation method of composition and drug and drug for treating diabetes | |
| CN108079000A (en) | A kind of pharmaceutical composition for treating diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB03 | Change of inventor or designer information |
Inventor after: Jin Jiahua Inventor after: Wang Biye Inventor after: Ding Liqin Inventor after: Cao Wujie Inventor after: Zhu Li Inventor after: Lan Tian Inventor after: Li Ning Inventor before: Jin Jiahua Inventor before: Wang Biye Inventor before: Ding Liqin Inventor before: Cao Wujie Inventor before: Zhu Li Inventor before: Lan Tian |
|
| CB03 | Change of inventor or designer information | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |